Ji Ma1,2, Yaru Tian1, Shaoyu Hao3, Liangjie Zheng2, Weibo Hu2, Xiaoyang Zhai1, Dongfang Meng1, Hui Zhu4. 1. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, 440 Jiyan Road, Jinan, 250117, Shandong Province, China. 2. Department of Oncology, The People's Hospital of Leling, Leling, China. 3. Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China. 4. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, 440 Jiyan Road, Jinan, 250117, Shandong Province, China. drzhuh@126.com.
Abstract
INTRODUCTION: Anti-programmed cell death-ligand 1 (Anti-PD-L1) blockades have become the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) from CASPIAN and IMpower133 trials. SCLC has a high incidence of brain metastasis (BM) and brain radiotherapy (BRT) is the main local treatment method, but there is limited data on the BRT-immunotherapy scheme. The aim of the retrospective study is to investigate the clinical efficacy and safety of the first-line anti-PD-L1 blockades combined with BRT in ES-SCLC with BM. METHODS: Patients with newly diagnosed ES-SCLC with baseline BMs at Shandong Cancer Hospital and Research Institute between 2017 and 2021 were selected. Patients were divided into the anti-PD-L1+BRT group and BRT group. We also assessed the leukoencephalopathy in both groups. RESULTS: A total of 46 patients were selected. Fifteen were divided into anti-PD-L1+BRT group and 31 to BRT group. The median overall survival (OS) was not reached (NR) vs 15.9 m (P = 0.172). Progression-free survival (PFS) was numerically prolonged with anti-PD-L1 blockades, but the significance was not reached (median: 9.4 m vs 7.4 m, P = 0.362). The median intracranial PFS was not improved, neither (median: 8.2 m vs 8.9 m, P = 0.620). Objective response rate (ORR) in the two groups was 73.33% vs 77.42% (P = 0.949) and disease control rate (DCR) was both 100%. Intracranial ORR and DCR were 53.33% vs 70.97% (P = 0.239) and 73.33% vs 80.65% (P = 0.855), respectively. There was no significant difference in leukoencephalopathy incidence between the two groups. CONCLUSION: The combination of first-line anti-PD-L1 blockades with BRT did not confer a significant survival benefit in ES-SCLC with BM, without enhancing cranial neurotoxicity.
INTRODUCTION: Anti-programmed cell death-ligand 1 (Anti-PD-L1) blockades have become the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) from CASPIAN and IMpower133 trials. SCLC has a high incidence of brain metastasis (BM) and brain radiotherapy (BRT) is the main local treatment method, but there is limited data on the BRT-immunotherapy scheme. The aim of the retrospective study is to investigate the clinical efficacy and safety of the first-line anti-PD-L1 blockades combined with BRT in ES-SCLC with BM. METHODS: Patients with newly diagnosed ES-SCLC with baseline BMs at Shandong Cancer Hospital and Research Institute between 2017 and 2021 were selected. Patients were divided into the anti-PD-L1+BRT group and BRT group. We also assessed the leukoencephalopathy in both groups. RESULTS: A total of 46 patients were selected. Fifteen were divided into anti-PD-L1+BRT group and 31 to BRT group. The median overall survival (OS) was not reached (NR) vs 15.9 m (P = 0.172). Progression-free survival (PFS) was numerically prolonged with anti-PD-L1 blockades, but the significance was not reached (median: 9.4 m vs 7.4 m, P = 0.362). The median intracranial PFS was not improved, neither (median: 8.2 m vs 8.9 m, P = 0.620). Objective response rate (ORR) in the two groups was 73.33% vs 77.42% (P = 0.949) and disease control rate (DCR) was both 100%. Intracranial ORR and DCR were 53.33% vs 70.97% (P = 0.239) and 73.33% vs 80.65% (P = 0.855), respectively. There was no significant difference in leukoencephalopathy incidence between the two groups. CONCLUSION: The combination of first-line anti-PD-L1 blockades with BRT did not confer a significant survival benefit in ES-SCLC with BM, without enhancing cranial neurotoxicity.
Authors: Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Luis Paz-Ares; Mikhail Dvorkin; Yuanbin Chen; Niels Reinmuth; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Oleksandr Voitko; Artem Poltoratskiy; Santiago Ponce; Francesco Verderame; Libor Havel; Igor Bondarenko; Andrzej Kazarnowicz; György Losonczy; Nikolay V Conev; Jon Armstrong; Natalie Byrne; Norah Shire; Haiyi Jiang; Jonathan W Goldman Journal: Lancet Date: 2019-10-04 Impact factor: 79.321
Authors: Apar Kishor P Ganti; Billy W Loo; Michael Bassetti; Collin Blakely; Anne Chiang; Thomas A D'Amico; Christopher D'Avella; Afshin Dowlati; Robert J Downey; Martin Edelman; Charles Florsheim; Kathryn A Gold; Jonathan W Goldman; John C Grecula; Christine Hann; Wade Iams; Puneeth Iyengar; Karen Kelly; Maya Khalil; Marianna Koczywas; Robert E Merritt; Nisha Mohindra; Julian Molina; Cesar Moran; Saraswati Pokharel; Sonam Puri; Angel Qin; Chad Rusthoven; Jacob Sands; Rafael Santana-Davila; Michael Shafique; Saiama N Waqar; Kristina M Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2021-12 Impact factor: 11.908
Authors: C J Twelves; R L Souhami; P G Harper; C M Ash; S G Spiro; H M Earl; J S Tobias; H Quinn; D M Geddes Journal: Br J Cancer Date: 1990-01 Impact factor: 7.640